Psychobiological and pharmacological studies of manic-depressive illness.
Psychobiological and pharmacological studies of manic-depressive illness.
复制标题
躁狂抑郁症的心理生物学和药理学研究。
DOI：
10.1016/0022-3956(72)90021-0
复制
发表时间：
1972
影响因子：
4.8
通讯作者：
F. Goodwin
中科院分区：
文献类型：
--
作者：
W. Bunney;E. Gershon;D. Murphy;F. Goodwin
THIS PAPER reviews a group of clinical, pharmacological and biological studies conducted over the last few years at the NIMH on manic-depressive illness. We will focus specifically on the use of L-dihydroxyphenylalanine (L-DOPA), the amino acid precursor of dopamine and norepinephrine, and alpha-methyl-para-tyrosine (aMPT), a specific inhibitor of tyrosine hydroxylase, the rate limiting step in the synthesis of dopamine and norepinephrine. The paper will further discuss the ‘switch process’ which is operationally defined as the events occurring at the time of change from depression into mania. Both spontaneous and drug related switches will be reviewed. Finally, a genetic dysfunction hypothesis of affective illness will be considered.The catecholamine theory of affective illness suggests that the brain neurotransmitters, norepinephrine and/or dopamine, are functionally decreased in depressionl, Z and increased in mania. 2 The tricyclic compounds and monoamine oxidase inhibitors (MAOI) commonly used to treat depression may increase functional levels of neurotransmitters in the brains of experimental animals. It has been hypothesized that this increase is related to their mode of action. However, these drugs are nonspecific in the sense that they affect indoleamines as well as catecholamines.
